Canada’s Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy

Research projects to have implications for cancer treatment worldwide
TORONTO, May 10 – Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG,
AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (Toronto,
Canada) will join their growing consortium to validate the clinical potential of
MRI-guided radiation therapy.

Sunnybrook Health Sciences Centre, the sixth largest cancer center in North
America, is the fourth member to sign the research agreement to evaluate the new
technology, which merges radiation therapy and magnetic resonance imaging (MRI)
in a single system. Current clinical members of the group include the University
Medical Center Utrecht, The University of Texas MD Anderson Cancer Center, and
The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital.

Integrating an advanced 1.5 Tesla MRI machine with a sophisticated radiation
therapy system will provide physicians with exceptional depictions of a
patient’s soft tissues and tumor and allow them to dynamically track their
motion. This breakthrough innovation is designed to permit doctors to deliver
radiation in real time under MR guidance for the most precise cancer treatments
possible.

“Sunnybrook Health Sciences Centre distinguishes itself in the world of science
and medicine by its longstanding dedication of integrating research into
clinical domain for the benefit of patients,” says Tomas Puusepp, Elekta
President and CEO. “With their international strength in the physical sciences –
particularly in imaging technology – and its worldwide repute as a top flight
cancer center, Sunnybrook is an ideal partner to help us advance this new
technology.”

According to Michael Julius, Vice President, Research at Sunnybrook Health
Sciences Centre, Sunnybrook’s participation in the research consortium will
bring a unique team of physicists, engineers and clinicians to focus on
validating the advantages of MRI-guided radiation therapy through technology
development and clinical trials.

“We have identified a number of areas to study the value of this technology for
patients,” he says. “The ultimate goal – acquiring high resolution MRI images of
pathology in real time as the radiation is being delivered – could have a
dramatic impact on patient health and clinical outcomes.”

Today, the safety margin of normal tissue around the tumor absorbs a large
portion of the radiation beam, adds Jean-Philippe Pignol, Professor of Radiation
Oncology and a key leader on the Elekta partnership at Sunnybrook’s Odette
Cancer Centre. “The expectation is that MR-guided radiation therapy will enable
us to treat more cancer tissue than normal tissue. In doing so, we could apply,
in a single fraction, a huge dose to the tumor while avoiding side effects to
normal tissues,” he says.

“The development of advanced imaging solutions for oncology therapy planning and
delivery is a key focus area for Philips,” says Gene Saragnese, CEO Imaging
Systems at Philips Healthcare. “Philips is already closely working together with
Sunnybrook Health Sciences Centre in this field, and we welcome their expertise
to the research consortium for MR guided radiotherapy. The members will jointly
work on the design and implementation of the clinical studies with the objective
of bringing image-guided oncology therapy to the next level, and ultimately
creating the future of healthcare.”

The integrated MRI-guided radiation therapy system is in development and not
available for sale.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

Steve Klink, Philips Corporate Communications
Tel: +31 20 5977415, email: steve.klink@philips.com

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on May 10, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

About Royal Philips Electronics
Royal Philips Electronics (NYSE: PHG, AEX: PHIA) is a diversified health and
well-being company, focused on improving people’s lives through meaningful
innovation in the areas of Healthcare, Consumer Lifestyle and Lighting.
Headquartered in the Netherlands, Philips posted 2012 sales of EUR 24.8 billion
and employs approximately 116,000 employees with sales and services in more than
100 countries. The company is a leader in cardiac care, acute care and home
healthcare, energy efficient lighting solutions and new lighting applications,
as well as male shaving and grooming and oral healthcare. News from Philips is
located at www.philips.com/newscenter.